Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Fineline Cube Aug 6, 2026
Company Drug

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Fineline Cube Aug 6, 2026
Company Medical Device

AstraZeneca Launches Evinova to Enhance Global Clinical Development with Digital Health Solutions

Fineline Cube Nov 21, 2023

UK-based AstraZeneca (AZ; NASDAQ: AZN) has launched Evinova, a digital health solutions provider, with the...

Company Drug

BMS and 2seventy Bio’s Abecma Faces FDA Review Extension

Fineline Cube Nov 21, 2023

The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...

Company Deals

Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project

Fineline Cube Nov 21, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company

Shanghai Pharmaceuticals’ Chairman Zhou Jun Resigns Amid Investigation

Fineline Cube Nov 21, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading Chinese pharmaceutical distribution company, has announced...

Company Deals

VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round

Fineline Cube Nov 21, 2023

China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of...

Company Drug

Jiangsu Aidea Pharmaceutical’s AINUOVIRINE Receives Priority Review Status from CDE

Fineline Cube Nov 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a Chinese pharmaceutical company, has announced that its...

Company Drug

Medilink Therapeutics’ YL201 Earns Orphan Drug Designation for Esophageal Cancer

Fineline Cube Nov 21, 2023

Suzhou-based Medilink Therapeutics has announced that it has obtained orphan drug designation (ODD) from the...

Company Deals

Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases

Fineline Cube Nov 21, 2023

Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co.,...

Company Deals

Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments

Fineline Cube Nov 21, 2023

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma...

Company Deals

Jiangsu Aidea Pharmaceutical Partners with Fidson Healthcare for HIV/AIDS Treatments in Nigeria

Fineline Cube Nov 20, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has reportedly entered into a strategic cooperation...

Company Deals

GE Healthcare’s Shanghai Innovation Hub Onboards Initial Start-Ups

Fineline Cube Nov 20, 2023

GE Healthcare’s (NASDAQ: GEHC) newly established Shanghai innovation center, dedicated to advancing healthcare projects, has...

Company Drug

BeiGene’s Brukinsa Secures Additional EU Approval for Follicular Lymphoma Treatment

Fineline Cube Nov 20, 2023

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has achieved its latest global approval for...

Company Deals

WuXi Biologics’ Subsidiary WuXi XDC Lists on Hong Kong Stock Exchange

Fineline Cube Nov 20, 2023

WuXi Biologics (HKG: 2269) has successfully spun off its conjugate drug-focused subsidiary, WuXi XDC Cayman...

Company Deals

Winning Health Partners with Shanghai Seventh People’s Hospital on Medical AI Services

Fineline Cube Nov 20, 2023

Shanghai-based medical information industry player, Winning Health (SHE: 300253), has announced a partnership with Shanghai...

Company Deals

Thermo Fisher Scientific Expands Partnership with Sangon Biotech to Include GC/MS

Fineline Cube Nov 20, 2023

US-based life sciences giant Thermo Fisher Scientific Inc., (NYSE: TMO) has announced an expansion of...

Company Deals

Usynova Pharmaceuticals Inks Licensing Deal with AstraZeneca for KRASG12D Inhibitor UA022

Fineline Cube Nov 20, 2023

Shanghai-based Usynova Pharmaceuticals Ltd has announced a licensing agreement with UK pharmaceutical major AstraZeneca (AZ,...

Company Drug

Ascentage Pharma Secures Additional Indication Approval for Olverembatinib from NMPA

Fineline Cube Nov 20, 2023

China-based Ascentage Pharma (HKG: 6855) has announced receiving another indication approval from the National Medical...

Company

Aurobindo Pharma’s China Plant Secures EU GMP Approval, Eyes Revenue Generation

Fineline Cube Nov 20, 2023

India-based Aurobindo Pharma reportedly received EU GMP approval for its China-based manufacturing plant last week,...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Phase II Clinical Study of ALMB-0168

Fineline Cube Nov 20, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...

Company Drug

Apollomics’ Partner Avistone Wins Conditional Approval for c-Met Inhibitor in China

Fineline Cube Nov 20, 2023

US-based biotech Apollomics Inc., (NASDAQ: APLM) has announced that its Chinese partner, Beijing Avistone Pharmaceuticals...

Posts pagination

1 … 479 480 481 … 704

Recent updates

  • Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance
  • Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer
  • Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%
  • CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer
  • Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Merck Reports Q2 2026 Sales of $16.6B, Driven by Keytruda Growth and Winrevair Surge as Company Raises Full-Year Guidance

Company Drug

Eli Lilly’s KRAS G12C Inhibitor Olomorasib Receives Second FDA Breakthrough Therapy Designation for Advanced Pancreatic Cancer

Company

Pfizer Reports Q2 2026 Revenue of $15.0B, Raises Full-Year Guidance as Launched and Acquired Products Surge 18%

Company Drug

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.